Integrating Mitochondrial Biology into Innovative Cell Therapies for Neurodegenerative Diseases
-
Published:2024-09-05
Issue:9
Volume:14
Page:899
-
ISSN:2076-3425
-
Container-title:Brain Sciences
-
language:en
-
Short-container-title:Brain Sciences
Author:
Ore Adaleiz12ORCID, Angelastro James M.1ORCID, Giulivi Cecilia13ORCID
Affiliation:
1. Department of Molecular Biosciences, School of Veterinary Medicine, University of California Davis, Davis, CA 95616, USA 2. Department of Chemical Engineering, School of Engineering, Case Western Reserve University, Cleveland, OH 44106, USA 3. University of California Medical Investigations of Neurodevelopmental Disorders Institute (MIND Institute), University of California Health, Sacramento, CA 95817, USA
Abstract
The role of mitochondria in neurodegenerative diseases is crucial, and recent developments have highlighted its significance in cell therapy. Mitochondrial dysfunction has been implicated in various neurodegenerative disorders, including Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis, and Huntington’s diseases. Understanding the impact of mitochondrial biology on these conditions can provide valuable insights for developing targeted cell therapies. This mini-review refocuses on mitochondria and emphasizes the potential of therapies leveraging mesenchymal stem cells, embryonic stem cells, induced pluripotent stem cells, stem cell–derived secretions, and extracellular vesicles. Mesenchymal stem cell–mediated mitochondria transfer is highlighted for restoring mitochondrial health in cells with dysfunctional mitochondria. Additionally, attention is paid to gene-editing techniques such as mito-CRISPR, mitoTALENs, mito-ZNFs, and DdCBEs to ensure the safety and efficacy of stem cell treatments. Challenges and future directions are also discussed, including the possible tumorigenic effects of stem cells, off-target effects, disease targeting, immune rejection, and ethical issues.
Funder
National Institutes of Health
Reference251 articles.
1. Lamptey, R.N.L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., and Singh, J. (2022). A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. Int. J. Mol. Sci., 23. 2. Drug treatments in Alzheimer’s disease;Briggs;Clin. Med.,2016 3. Choi, H.S., and Cho, S.H. (2022). Effects of Multimodal Rehabilitation on the Activities of Daily Living, Quality of Life, and Burden of Care for Patients with Parkinson’s Disease: A Randomized Control Study. Healthcare, 10. 4. Vieira, F.G., LaDow, E., Moreno, A., Kidd, J.D., Levine, B., Thompson, K., Gill, A., Finkbeiner, S., and Perrin, S. (2014). Dexpramipexole is ineffective in two models of ALS related neurodegeneration. PLoS ONE, 9. 5. Mitochondrial dysfunction in Parkinson’s disease—A key disease hallmark with therapeutic potential;Henrich;Mol. Neurodegener.,2023
|
|